Personalized Medicine: Challenging Pharmaceutical and Diagnostic Company Business Models by Ferrara, Joseph
59 MJM 2007 10(1):59-61 Copyright © 2007 by MJM
FEATURE REVIEW
Personalized Medicine: Challenging




The phrase "Personalized Medicine" has been
alternately broadly and narrowly defined. Under its
broadest definition, clinicians have been have been
providing personalized medicine for as long as there has
been medical practice - physicians employ diagnostic
tools, whether in vitro tests, imaging techniques, or
symptomology to determine a particular condition, and
then go on to prescribe the appropriate treatment, drug
or otherwise. 
However, it is pharmacogenomics -- the ability to test
for variations in genes and their expression through
molecular diagnostics and then to treat with targeted
drugs -- that shapes a narrower, and more potent,
definition of personalized medicine. For patients and
physicians, personalized medicine offers apparently
clear clinical advantages -- a biomarker points directly
to the most appropriate therapeutic intervention.  This in
turn leads to more predictable outcomes, enhanced
efficacy through the identification of drug responders,
and a potential reduction in adverse drug reactions.
This would be a sea change for at least some of medical
practice, where certain drugs may now be prescribed on
something of a trial and error basis and the therapy
effective for only a portion of the treated patients.   
While personalized medicine offers the potential to
change well-established practices for physicians and
patients, the concept presents a direct challenge to the
business models of two other health care stakeholders
essential to the realization of personalized medicine-
pharmaceutical and diagnostics companies. At the core
of the challenge is a central question- how will a
personalized medicine paradigm change these
companies' innovation and commercialization
approaches?  This question can be aimed at nearly every
aspect of these stakeholders' current strategies- how
clinical trials are conducted, the depth and breadth of
the clinical evidence developed, and, perhaps most




Pharmacogenomics is a growing component of drug
development, but drug companies' desire to sell
blockbuster drugs (drugs with annual sales of one
billion dollars or more) will not disappear anytime soon.
The blockbuster model has dominated R&D and
commercialization planning for large pharmaceutical
companies since the 1980s.  In 2002, biopharmaceutical
companies marketed 40 blockbuster drugs with total
sales of nearly $90 billion. However, studies have
shown that many of these drugs may be efficacious in
only slim majority of the prescribed population. The
model is so entrenched, that physicians often prescribe
these drugs on a trial and error basis. And, of course,
these drugs demand large, expensive trials. However,
drug companies' substantial investment in R&D to find
more of these drugs has yet to yield a proportional
increase in new approved drugs. 
With such a low yielding research investment
environment, pharmacogenomics offers the potential at
least, to make up some of the shortfall. In 2005, the
FDA created guidance for drug developers to link
biomarkers to therapeutics in the clinical development
process. The FDA views pharmacogenomics as a key
tool for optimizing both the development and clinical
utility of drugs.
Perhaps not surprisingly, the majority of
diagnostic/pharmaceutical (Dx/Rx) combinations are in
oncology. Besides being a major magnet for60 McGill Journal of Medicine 2007
pharmaceutical R&D investment, oncology presents a
tailor-made target for pharmacogenomics- cancer is a
complex, multi-factorial disease.  It is also a clinical
area many stakeholders, not just industry, view as an
optimal target for Dx/Rx combinations- the disease is
life threatening, the drugs often have brutal side effects,
and these treatments are often very expensive.
Identifying tests that can help target these drugs to only
those patients that benefit most has great value in this
clinical area.        
With all of these potential benefits to
pharmacogenomics, some drug companies have
responded by increasing their investment in the Dx/Rx
approach. The number of INDs/NDAs using
pharmacogenomic biomarkers has increased from less
than 20 filings between 1995 and 2000 to nearly 100
filings in the 2002-2003 period alone.  Many of the
filings have been in oncology, and based on an analysis
of the current cancer pipeline and estimated clinical trial
success rates, there may be as many as 35 new targeted
cancer therapies on the US market by 2012.  And while
all of these drugs could be candidates for a Dx/Rx
combination, just how many of these drugs will launch
with a companion diagnostic test remains to be seen
because of the unpredictability of these combinations in
clinical development and practice.  
Drug companies have had mixed results in effectively
incorporating diagnostic biomarkers into clinical
development programs and then launching the
combination. The most well known Dx/Rx combination
is the HercepTest®/trastuzumab (Herceptin®)
combination from Dako and Genentech/Roche for the
Her2-positive subset of breast cancer patients.
However, less successful In terms of Dx / Rx pairings
have been the cases of cetuximab (Erbitux®) and
gefitinib (Iressa®). As has been widely documented,
both cases have demonstrated that it can be difficult to
predict which drugs will benefit from companion
biomarkers, with some studies showing that cefitinib
(launched with a companion EGFR test) may have a
benefit in a portion of EGFR-negative patients and
gefitinib (launched without a companion test) may
indeed need a test to identify the subset of optimal
responders.      
The difficulty in predicting the clinical utility of
biomarkers in drug development in tandem with the
perceived threat to the blockbuster model means that
pharmaceutical companies have embraced
pharmacogenomics with varying degrees of enthusiasm
and investment.  Although several drug companies have
publicly committed to developing and launching drugs
with attendant diagnostic tests, it is difficult to imagine
that these companies will abandon the quest for the
billion dollar drug in favor of an rarely proven
pharmacogenomic commercial model. Most likely, big
drug companies will take a "both-and" approach to drug
development and commercialization-continuing to
pursue the high revenue potential of a "one-size-fits-
most" product while opportunistically incorporating
pharmacogenomics approaches. Success in the latter
will much depend on the relationships that
pharmaceutical players develop, directly or indirectly,
collaborative or adversarial, with the other key player in
the tandem- diagnostics companies.
DIAGNOSTICS COMPANIES: PURSUING
VALUE-BASED RECOGNITION
It is the diagnostics companies that have the most to
gain in the near term from the realization of
personalized medicine. This is largely because in vitro
diagnostics are currently so undervalued compared to
their drug counterparts in the first place.
For example, in the US, for every ten dollars that
Medicare spends on pharmaceuticals, the agency
spends roughly $1.60 on lab services. And laboratory
services influence not only pharmaceutical therapy
selection, but other interventions as well-- perhaps as
much as 60% to 70% of health care expenditures
according to some studies.
However, the system that payers use to reimburse for
diagnostics has become a limiting factor in the ability
for innovative diagnostics to be appropriately valued in
the commercial environment. Currently, payers
reimburse for laboratory services using what is largely
a cost-based system, not a value-based system.  
Currently, payment amounts for new tests are
typically established relative to older tests with similar
analytical methodologies.  Thus, any new immunoassay
will likely be reimbursed at a rate similar to established
immunoassays. The same is true in molecular
diagnostics. Any new test using established nucleic acid
analytical methodologies will be paid the same amounts
as older tests using the same methodologies, ignoring
the likely difference in reagent expenses between the
older and the newer tests.  It would be as if all novel
injectable drugs were reimbursed at the same amounts
as injectables that have been on the market for many
years. Such an approach does not allow for a novel
payment amount to be applied to a novel test- a
payment amount that could be related to the test's
perceived clinical value, for example.  
To see how this cost-based system has hampered
value creation for the diagnostics industry, one needs
only to look at the trend in Medicare reimbursement
rates over the last twenty years.  For example, a test that
was paid at $10 on average in the mid 1980s is now
paid at about perhaps $8 after adjusting for inflation.
Stakeholders, and not just industry groups, understand
the value of innovation in medicine. A decline in
payment of 20% in real dollars over two decades is not61 Personalized Medicine Vol. 10  No. 1
an environment conducive to the innovation that will be
required to drive pharmacogenomics and personalized
medicine.
Conceptually, personalized medicine could allow for
a reconfiguration of the value of the parts in the Dx/Rx
whole.  The idea is that payers will begin to look at the
diagnostic as an increasingly valuable tool that can help
manage the appropriate use of expensive drugs.  If a test
can be used to avoid even a few months of an expensive
prescription for a non-responder, the test marketer can,
in theory at least, capture some of this enhanced value. 
Diagnostics players understand this, and are
attempting to capture novel value for their novel tests in
the Dx/Rx paradigm. Logically, developing tests that
will distinguish responders from non-responders for
expensive drugs or drugs with dangerous side effects is
a priority offering both clinical and economic value.  To
meet this objective, diagnostics companies are
deploying two basic business models, each with
different approaches to clinical development and
market risk.  
The longer-term opportunity for these diagnostics
companies will be to link test development programs to
drug development programs and then launching the
approved drug and test as a true tandem from the outset.
In this way, compelling clinical evidence for the test and
drug will be developed by design, supporting the value
of the Dx/Rx combination. While a diagnostics
company is not taking the same clinical development
risk and making the same scale of investment as the
drug company in such a model, many of the drugs
developed may not be approved, and thus a test could be
developed that may never see the market.       
A nearer-term opportunity for diagnostics companies
is the development of tests that are linked to currently
marketed therapies. Currently marketed drugs that
could benefit from a test to identify optimal responders
are near-term target markets for diagnostics companies.
Of course, diagnostics companies that launch tests
linked to currently marketed drugs will likely seek
reimbursement from payers that reflects the perceived
value of their innovation. To do so, these companies
will have to take control of the reimbursement process,
perhaps working outside of established test payment
mechanisms such as payer clinical lab fee schedules, to
seek a payment rate not tied to established tests or
methodologies.  In order to this, diagnostics companies
will have to develop adequate clinical data to support
positive coverage of the test by payers, and accordingly
positive payment. 
PERSONALIZED MEDICINE WILL REQUIRE
HEALTH CARE STAKEHOLDER
COLLABORATION
The development and delivery of the necessary
component parts for personalized medicine solutions
will continue to come from numerous industries. This
raises an important question-- how will the range of
health care stakeholders work together to develop and
deploy innovative technologies for personalized
medicine?  
The circumstances that will allow personalized
medicine to flourish are just beginning to take shape.
Stakeholders are moving forward with research
investment, new models for collaboration, and
developing regulatory and policy approaches that can
allow for these technologies to emerge. In addition to
the FDA guidance on pharmacogenomics in drug
development, payers, both government and private, are
developing methodologies for translating clinical
evidence into policies that will guide insurance
payment. And this may be the most challenging issue of
all for personalized medicine-developing a policy
approach that allows access to these technologies for
right patients given the highly targeted nature of
personalized medicine. By design, the policy-making
environment was formed on a foundation of broadly
applicable therapies.  For policy makers the question is
this- how can policies be developed when many
treatments may be decided on a highly varied case-by-
case basis?  Do we even have the analytical tools and
information technology infrastructure to analyze the
clinical and economic effectiveness of these highly
targeted approaches?  
As these efforts continue, it will be essential for
diagnostics and pharmaceutical companies, payers,
physicians, and patient groups to interact to create an
environment that is favorable to both the basic research
that is required for innovation of effective personalized
medicine solutions, as well as their eventual
commercialization. 
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